TLR2 antagonist / EVER Pharma - LARVOL DELTA

Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson’s Research to Support Development of Its TLR2 Program (Businesswire) - "Neuropore Therapies, Inc...announced today that it received a $4.8M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule Toll-Like receptor 2 (TLR2) antagonist...'This grant will help enable us to rapidly advance our lead TLR2 antagonist through preclinical and early clinical development'..."

Financing • CNS Disorders • Parkinson's Disease